Case Report - (2024) Volume 10, Issue 4
Pembrolizumab has been approved by the Food and Drug Administration (FDA) to treat multiple cancers one of which is triple-negative breast cancer positive for Programmed Cell Death Ligand 1 (PD-L1) protein. Multiple immune-related Adverse Drug Reactions (irADRs) have been reported with pembrolizumab affecting various organ systems. Bell's palsy is one such irADR that has been previously reported with Immune Checkpoint Inhibitors (ICI) use in other cancers, but it has not been reported in triple-negative breast cancer. We present a case of a 35-year-old woman with Bell's Palsy (lower motor neuron type), with a history of triple negative stage 2 invasive ductal carcinoma receiving neoadjuvant chemoimmunotherapy with pembrolizumab. She presented with right-sided facial drooping affecting the upper and lower part with impaired sensation on the left side of the face. After an extensive workup, a diagnosis of Bell's Palsy was made which was attributed to treatment with pembrolizumab.. She was treated with high-dose steroids resulting in symptom resolution. We are reporting this case to emphasize that if anyone on ICI therapy for solid cancers has atypical presentation with non-focal symptoms, ICI induced Bell’s Palsy should be kept high on differentials, even if there is no reported incidence in that particular cancer.
The Publisher and Editor regretfully retract the article titled "Pembrolizumab Induced Bell’s Palsy in Triple Negative Breast Cancer: A Case Report” “Oncology and Cancer Case Reports” Volume 10, Issue 04, and Page no. 01-03. Following an investigation which found that the author violated the Journal's policy and putting false allegations towards to the journal. This is contrary to the ethical standards of the journal and unacceptable. The author denied to support open access. The authors have been notified of this decision. The Publisher and Editor apologize to the readers of the journal for any inconvenience this may cause
Citation: Bipasha F., Pembrolizumab Induced Bell’s Palsy in Triple Negative Breast Cancer: A Case Report. Oncol Cancer Case Rep. 2024, 10 (4), 001-003
Received: 21-Sep-2024, Manuscript No. OCCRS-24-148563; Editor assigned: 26-Sep-2024, Pre QC No. OCCRS-24-148563(PQ); Reviewed: 07-Oct-2024, QC No. OCCRS-24-148563(Q); Revised: 21-Oct-2024, Manuscript No. OCCRS-24-148563(R); Published: 20-Nov-2024, DOI: 10.35248/2332-2594.22.10(4).001-003
Copyright: ©2024 Bipasha F. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.